decitabine
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Trial Timeline
Jul 1, 2007 → Dec 1, 2009
NCT ID
NCT00538876About decitabine
decitabine is a phase 1 stage product being developed by Eisai for Acute Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00538876. Target conditions include Acute Myeloid Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00538876 | Phase 1 | Completed |
| NCT00477386 | Phase 1/2 | Completed |
| NCT00398983 | Phase 2/3 | Completed |
| NCT00349596 | Phase 1 | Completed |
| NCT00760084 | Phase 2 | Completed |
| NCT00260065 | Phase 2 | Completed |
| NCT00358644 | Phase 2 | Completed |
| NCT00113321 | Phase 2 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukemia